Búsqueda | Portal de Búsqueda de la BVS España

1.

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.

Malcovati, Luca; Stevenson, Kristen; Papaemmanuil, Elli; Neuberg, Donna; Bejar, Rafael; Boultwood, Jacqueline; Bowen, David T; Campbell, Peter J; Ebert, Benjamin L; Fenaux, Pierre; Haferlach, Torsten; Heuser, Michael; Jansen, Joop H; Komrokji, Rami S; Maciejewski, Jaroslaw P; Walter, Matthew J; Fontenay, Michaela; Garcia-Manero, Guillermo; Graubert, Timothy A; Karsan, Aly; Meggendorfer, Manja; Pellagatti, Andrea; Sallman, David A; Savona, Michael R; Sekeres, Mikkael A; Steensma, David P; Tauro, Sudhir; Thol, Felicitas; Vyas, Paresh; Van de Loosdrecht, Arjan A; Haase, Detlef; Tüchler, Heinz; Greenberg, Peter L; Ogawa, Seishi; Hellstrom-Lindberg, Eva; Cazzola, Mario.

Blood; 136(2): 157-170, 2020 07 09.

Artículo en Inglés | MEDLINE | ID: mdl-32347921

2.

Novel somatic mutations in UBA1 as a cause of VEXAS syndrome.

Poulter, James A; Collins, Jason C; Cargo, Catherine; De Tute, Ruth M; Evans, Paul; Ospina Cardona, Daniela; Bowen, David T; Cunnington, Joanna R; Baguley, Elaine; Quinn, Mark; Green, Michael; McGonagle, Dennis; Beck, David B; Werner, Achim; Savic, Sinisa.

Blood; 137(26): 3676-3681, 2021 07 01.

Artículo en Inglés | MEDLINE | ID: mdl-33690815

3.

Telomere length is an independent prognostic marker in MDS but not in de novo AML.

Williams, Jenna; Heppel, Nicole H; Britt-Compton, Bethan; Grimstead, Julia W; Jones, Rhiannon E; Tauro, Sudhir; Bowen, David T; Knapper, Steven; Groves, Michael; Hills, Robert K; Pepper, Chris; Baird, Duncan M; Fegan, Chris.

Br J Haematol; 178(2): 240-249, 2017 07.

Artículo en Inglés | MEDLINE | ID: mdl-28486748

4.

Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.

Cargo, Catherine A; Rowbotham, Nicola; Evans, Paul A; Barrans, Sharon L; Bowen, David T; Crouch, Simon; Jack, Andrew S.

Blood; 126(21): 2362-5, 2015 Nov 19.

Artículo en Inglés | MEDLINE | ID: mdl-26392596

5.

Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes.

Mastaglio, Francesca; Bedair, Khaled; Papaemmanuil, Elli; Groves, Michael J; Hyslop, Ann; Keenan, Norene; Hothersall, Eleanor J; Campbell, Peter J; Bowen, David T; Tauro, Sudhir.

Br J Haematol; 174(2): 227-34, 2016 07.

Artículo en Inglés | MEDLINE | ID: mdl-27098194

6.

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Malcovati, Luca; Papaemmanuil, Elli; Bowen, David T; Boultwood, Jacqueline; Della Porta, Matteo G; Pascutto, Cristiana; Travaglino, Erica; Groves, Michael J; Godfrey, Anna L; Ambaglio, Ilaria; Gallì, Anna; Da Vià, Matteo C; Conte, Simona; Tauro, Sudhir; Keenan, Norene; Hyslop, Ann; Hinton, Jonathan; Mudie, Laura J; Wainscoat, James S; Futreal, P Andrew; Stratton, Michael R; Campbell, Peter J; Hellström-Lindberg, Eva; Cazzola, Mario.

Blood; 118(24): 6239-46, 2011 Dec 08.

Artículo en Inglés | MEDLINE | ID: mdl-21998214

7.

Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome.

Mills, Ken I; Kohlmann, Alexander; Williams, P Mickey; Wieczorek, Lothar; Liu, Wei-min; Li, Rachel; Wei, Wen; Bowen, David T; Loeffler, Helmut; Hernandez, Jesus M; Hofmann, Wolf-Karsten; Haferlach, Torsten.

Blood; 114(5): 1063-72, 2009 Jul 30.

Artículo en Inglés | MEDLINE | ID: mdl-19443663

8.

Epigenetic mechanisms regulating normal and malignant haematopoiesis: new therapeutic targets for clinical medicine.

Bonifer, Constanze; Bowen, David T.

Expert Rev Mol Med; 12: e6, 2010 Feb 15.

Artículo en Inglés | MEDLINE | ID: mdl-20152067

9.

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.

Zeidan, Amer M; Boddu, Prajwal C; Patnaik, Mrinal M; Bewersdorf, Jan Philipp; Stahl, Maximilian; Rampal, Raajit K; Shallis, Rory; Steensma, David P; Savona, Michael R; Sekeres, Mikkael A; Roboz, Gail J; DeAngelo, Daniel J; Schuh, Andre C; Padron, Eric; Zeidner, Joshua F; Walter, Roland B; Onida, Francesco; Fathi, Amir; DeZern, Amy; Hobbs, Gabriela; Stein, Eytan M; Vyas, Paresh; Wei, Andrew H; Bowen, David T; Montesinos, Pau; Griffiths, Elizabeth A; Verma, Amit K; Keyzner, Alla; Bar-Natan, Michal; Navada, Shyamala C; Kremyanskaya, Marina; Goldberg, Aaron D; Al-Kali, Aref; Heaney, Mark L; Nazha, Aziz; Salman, Huda; Luger, Selina; Pratz, Keith W; Konig, Heiko; Komrokji, Rami; Deininger, Michael; Cirici, Blanca Xicoy; Bhatt, Vijaya Raj; Silverman, Lewis R; Erba, Harry P; Fenaux, Pierre; Platzbecker, Uwe; Santini, Valeria; Wang, Eunice S; Tallman, Martin S.

Lancet Haematol; 7(8): e601-e612, 2020 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-32563283

10.

Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients.

Bowen, David T; Hellström-Lindberg, Eva; Steensma, David P.

Br J Haematol; 164(4): 610-1, 2014 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-24236802

11.

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation.

Liberante, Fabio G; Pellagatti, Andrea; Boncheva, Viktoriya; Bowen, David T; Mills, Ken I; Boultwood, Jacqueline; Guinn, Barbara-Ann.

Br J Haematol; 162(2): 282-5, 2013 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-23594062

12.

Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study.

Durairaj, Senthilkumar; Keenan, Norene; Hyslop, Ann; Groves, Michael J; Bowen, David T; Tauro, Sudhir.

Br J Haematol; 161(2): 280-2, 2013 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-23294041

13.

Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors.

Biedermann, Bjoern; Gil, Diana; Bowen, David T; Crocker, Paul R.

Leuk Res; 31(2): 211-20, 2007 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-16828866

14.

Etiology of acute myeloid leukemia in the elderly.

Bowen, David T.

Semin Hematol; 43(2): 82-8, 2006 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-16616041

15.

Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.

Bowen, David T.

Semin Oncol; 32(4 Suppl 5): S16-23, 2005 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-16085013

16.

An intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AML.

Dukka, Srivasavi; Bowen, David T.

Leuk Res Rep; 4(1): 18-20, 2015.

Artículo en Inglés | MEDLINE | ID: mdl-25709893

17.

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).

Fidler, Carrie; Watkins, Fiona; Bowen, David T; Littlewood, Timothy J; Wainscoat, James S; Boultwood, Jacqueline.

Haematologica; 89(7): 865-6, 2004 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-15257941

18.

Latency of onset of de novo myelodysplastic syndromes.

Wu, Pei-shan; Hay, Annette E; Thomas, Giles E; Bowen, David T.

Haematologica; 89(11): 1392-4, 2004 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-15531463

19.

Oxidative stress and the myelodysplastic syndromes.

Farquhar, Morag J; Bowen, David T.

Int J Hematol; 77(4): 342-50, 2003 May.

Artículo en Inglés | MEDLINE | ID: mdl-12774921

20.

Occupational and environmental etiology of MDS.

Bowen, David T.

Best Pract Res Clin Haematol; 26(4): 319-26, 2013 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-24507809

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.

Novel somatic mutations in UBA1 as a cause of VEXAS syndrome.

Telomere length is an independent prognostic marker in MDS but not in de novo AML.

Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.

Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes.

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome.

Epigenetic mechanisms regulating normal and malignant haematopoiesis: new therapeutic targets for clinical medicine.

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.

Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients.

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation.

Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study.

Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors.

Etiology of acute myeloid leukemia in the elderly.

Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.

An intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AML.

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).

Latency of onset of de novo myelodysplastic syndromes.

Oxidative stress and the myelodysplastic syndromes.

Occupational and environmental etiology of MDS.